GlassScriptPhysician profile
Heather Graham
NPI 1326714189
$6,311.77
in general payments reported to CMS, 2019-2025
23 companies · $2,742 in 2025
The $2,742 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $886 · 2023: $990 · 2024: $1,508 · 2025: $2,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,855 · Travel and Lodging: $1,339 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,854.91 |
| Travel and Lodging | $1,339.46 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,194.68 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Averitas Pharma INC. | $1,099.52 | 2023-2025 | Qutenza |
| Abbott Laboratories | $574.96 | 2021-2025 | Proclaim, Eterna |
| Scilex Pharmaceuticals INC. | $350.78 | 2023-2025 | Ztlido |
| Abbvie INC. | $299.39 | 2022-2025 | |
| Pfizer INC. | $269.66 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $215.74 | 2022 | |
| Collegium Pharmaceutical, INC. | $165.98 | 2022-2025 | Xtampza, Belbuca |
| Ibsa Pharma INC. | $163.86 | 2023-2024 | Licart, Tirosint, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.59 | 2025 | Relistor |
| Horizon Therapeutics Plc | $136.17 | 2021-2022 | |
| Nevro Corp. | $129.72 | 2021-2022 | |
| Csl Behring | $114.05 | 2023-2025 | Hizentra |
| Grt US Holding, INC. | $102.62 | 2022 | |
| Boston Scientific Corporation | $88.17 | 2024-2025 | Accolade Sr, Wavewriter Alpha Prime 16 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $60.39 | 2023-2024 | Xeomin |
| Allergan, INC. | $59.03 | 2021-2022 | |
| Globus Medical, INC. | $31.41 | 2025 | Senza |
| Fidia Pharma USA INC. | $29.37 | 2023-2024 | Triluron, Hymovis, Hyalgan |
| Ipsen Biopharmaceuticals, INC | $25.63 | 2025 | Dysport |
| Amgen INC. | $24.03 | 2022 | |
| Nalu Medical, INC. | $18.66 | 2023 | Nalu Neurostimulation System |
| Lilly USA, LLC | $18.36 | 2023 | Reyvow, Emgality |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.